^
Association details:
| Biomarker: | RB1 mutation + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
/ 7 - Alterations in key cell cycle-related genes and prognostic value for early breast cancer patients
Published date:
05/15/2020
Excerpt:
The most commonly altered CCGs were CCND1 (14%), CDKN1B (3%), CDK4 (3%), CCND2 (2%), and RB1(2%) in HR+/HER2- EBC…10 metastatic BC patients with HR+/HER2- were treated by palbociclib, and 6 patients with CCGs alterations showed partial response (n=1) and stable disease (n=5).
